Ovoca Bio PLC
LSE:OVB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.55
1.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ovoca Bio PLC
Ovoca Bio PLC
Accounts Receivables
Ovoca Bio PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ovoca Bio PLC
LSE:OVB
|
Accounts Receivables
€175k
|
CAGR 3-Years
25%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Accounts Receivables
$813.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Accounts Receivables
$723.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Accounts Receivables
$37.1m
|
CAGR 3-Years
412%
|
CAGR 5-Years
32%
|
CAGR 10-Years
29%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Accounts Receivables
€23.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
3%
|
|
Ovoca Bio PLC
Glance View
Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.
See Also
What is Ovoca Bio PLC's Accounts Receivables?
Accounts Receivables
175k
EUR
Based on the financial report for Jun 30, 2024, Ovoca Bio PLC's Accounts Receivables amounts to 175k EUR.
What is Ovoca Bio PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
-7%
Over the last year, the Accounts Receivables growth was -17%. The average annual Accounts Receivables growth rates for Ovoca Bio PLC have been 25% over the past three years , 2% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
